Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034

Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034

The Viral Vectors and Plasmid DNA Manufacturing Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Viral vectors and plasmids are instrumental in the field of biotechnology, especially in the context of advancements like CRISPR-Cas9 gene editing. They serve as indispensable vehicles for delivering genetic material with precision, enabling scientists to manipulate and modify genes for various purposes, from basic research to therapeutic interventions. Viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, have become central players in gene therapy, allowing for the targeted insertion of genetic material into host cells. Plasmids, on the other hand, are versatile circular pieces of DNA commonly used in molecular biology research to introduce foreign genes into cells or organisms. Their importance extends beyond gene editing to encompass a wide array of biotechnological applications, including vaccine development and protein production.

Recent developments in the biotechnology landscape further underscore the critical role of viral vectors and plasmids. In January 2023, Catalent, a prominent player in the biopharmaceutical industry, inaugurated a state-of-the-art plasmid DNA (pDNA) manufacturing facility in Gosselies, Belgium. This facility not only signifies the growing demand for plasmids but also the need for their efficient production at a commercial scale. Catalent's commitment to producing off-the-shelf plasmids to support cell and gene companies reflects the broader trend in the industry, where these genetic tools are in high demand. The integration of pDNA expertise in Gosselies with the clinical and commercial production of viral vectors for gene therapy, cell therapy, and mRNA across their network is a strategic move that ensures the continuity of the supply chain. It's a testament to the interdependence of these elements in the biotechnology ecosystem and their collective role in driving therapeutic innovations.

What Questions Should You Ask before Buying a Market Research Report?

• How is the viral vectors and plasmid DNA manufacturing market evolving?
• What is driving and restraining the viral vectors and plasmid DNA manufacturing market?
• How will each viral vectors and plasmid DNA manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each viral vectors and plasmid DNA manufacturing submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading viral vectors and plasmid DNA manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the viral vectors and plasmid DNA manufacturing projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of viral vectors and plasmid DNA manufacturing projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the viral vectors and plasmid DNA manufacturing market?
• Where is the viral vectors and plasmid DNA manufacturing market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the viral vectors and plasmid DNA manufacturing market today, and over the next 10 years:

• Our 408-page report provides 166 tables, 183 charts /graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Viral Vectors and Plasmid DNA Manufacturing Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising viral vectors and plasmid DNA manufacturing prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Vector Type

• Adenovirus
• Retrovirus
• Plasmid DNA
• AAV
• Lentivirus
• Other Vectors

Application

• Antisense and RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology

End-use

• Pharma and Biopharma Companies
• Research Institutes

Disease

• Oncology
• Genetic Disorders
• Infectious Diseases
• Others Diseases

Workflow

• Upstream
• Downstream

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Sweden
• Switzerland
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Taiwan
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• Addgene
• Advanced BioScience Laboratories, Inc. (ABL)
• Aldevron
• Altogen Biosystems
• Amicus Therapeutics
• ATUM
• Batavia Biosciences B.V.
• BioNTech IMFS
• Biovian Oy
• bluebird bio Inc.
• Catalent Inc.
• CEVEC Pharmaceuticals GmbH
• Charles River Laboratories
• Creative Biogene
• FUJIFILM Diosynth Biotechnologies
• GENEZEN
• Lonza
• Merck KGaA
• Recipharm AB
• Thermo Fisher Scientific Inc.
• uniQure N.V.
• VGXI Inc.
• Virovek
• VIVEbiotech
• Waisman Biomanufacturing
• WuXi AppTec
• Yposkesi, Inc.

Overall world revenue for viral vectors and plasmid DNA manufacturing market, 2024 to 2034 in terms of value the market will surpass US$1,350 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034 report help you?

In summary, our 400+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034, with forecasts for vector types, application, and end-use, disease and workflow each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 24 key national markets – See forecasts for the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Sweden, Switzerland, China, India, Japan, Australia, South Korea, Singapore, Taiwan, Brazil, Mexico, Argentina, GCC, South Africa, and among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 27 of the major companies involved in the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.